Primary biliary cholangitis (English Wikipedia)

Thain C (2015). "Primary Biliary Cirrhosis: Getting a Diagnosis". At Home Magazine. Archived from the original (online) on 13 July 2015. Retrieved 28 July 2015.

bham.ac.uk

pure-oai.bham.ac.uk

Hirschfield, Gideon M.; Beuers, Ulrich; Corpechot, Christophe; Invernizzi, Pietro; Jones, David; Marzioni, Marco; Schramm, Christoph (July 2017). "EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis" (PDF). Journal of Hepatology. 67 (1): 145–172. doi:10.1016/j.jhep.2017.03.022. PMID 28427765.

books.google.com

Dancygier H (2010). Principles and Practice of Clinical Hepatology. Springer. pp. 895–. ISBN 978-3-642-04509-7. Retrieved 29 June 2010.
Bacon BR, O'Grady JG (2006). Comprehensive Clinical Hepatology. Elsevier Health Sciences. pp. 283–. ISBN 978-0-323-03675-7. Retrieved 29 June 2010.

doi.org

Poupon R (May 2010). "Primary biliary cirrhosis: a 2010 update". Journal of Hepatology. 52 (5): 745–758. doi:10.1016/j.jhep.2009.11.027. PMID 20347176.
Hirschfield GM, Gershwin ME (January 2013). "The immunobiology and pathophysiology of primary biliary cirrhosis". Annual Review of Pathology. 8: 303–330. doi:10.1146/annurev-pathol-020712-164014. PMID 23347352.
Selmi C, Bowlus CL, Gershwin ME, Coppel RL (May 2011). "Primary biliary cirrhosis". Lancet. 377 (9777): 1600–1609. doi:10.1016/S0140-6736(10)61965-4. PMID 21529926. S2CID 2741153.
Boonstra K, Beuers U, Ponsioen CY (May 2012). "Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review". Journal of Hepatology. 56 (5): 1181–1188. doi:10.1016/j.jhep.2011.10.025. PMID 22245904.
James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV (August 1999). "Primary biliary cirrhosis once rare, now common in the United Kingdom?". Hepatology. 30 (2): 390–394. doi:10.1002/hep.510300213. PMID 10421645. S2CID 25248575.
Moulton, Vaishali R. (2018). "Sex Hormones in Acquired Immunity and Autoimmune Disease". Frontiers in Immunology. 9: 2279. doi:10.3389/fimmu.2018.02279. ISSN 1664-3224. PMC 6180207. PMID 30337927.
Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ (July 2009). "Primary biliary cirrhosis". Hepatology. 50 (1): 291–308. doi:10.1002/hep.22906. PMID 19554543. S2CID 439839. The AASLD Practice Guideline
Floreani A, Franceschet I, Cazzagon N (August 2014). "Primary biliary cirrhosis: overlaps with other autoimmune disorders". Seminars in Liver Disease. 34 (3): 352–360. doi:10.1055/s-0034-1383734. hdl:11577/3143751. PMID 25057958. S2CID 21382956.
Vierling JM (February 2004). "Primary Biliary Cirrhosis and Autoimmune Cholangiopathy". Clinics in Liver Disease. 8 (1): 177–194. doi:10.1016/S1089-3261(03)00132-6. PMID 15062200.
Narciso-Schiavon JL, Schiavon LL (February 2017). "To screen or not to screen? Celiac antibodies in liver diseases". World Journal of Gastroenterology (Review). 23 (5): 776–791. doi:10.3748/wjg.v23.i5.776. PMC 5296194. PMID 28223722.
Volta U, Rodrigo L, Granito A, Petrolini N, Muratori P, Muratori L, et al. (October 2002). "Celiac disease in autoimmune cholestatic liver disorders". The American Journal of Gastroenterology. 97 (10): 2609–2613. doi:10.1111/j.1572-0241.2002.06031.x. PMID 12385447. S2CID 17375127.
Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. (June 2009). "Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants". The New England Journal of Medicine. 360 (24): 2544–2555. doi:10.1056/NEJMoa0810440. PMC 2857316. PMID 19458352.
Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, et al. (October 2012). "Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis". Nature Genetics. 44 (10): 1137–1141. doi:10.1038/ng.2395. PMC 3459817. PMID 22961000.
Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, et al. (December 2012). "Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants". Human Molecular Genetics. 21 (23): 5209–5221. doi:10.1093/hmg/dds359. PMC 3490520. PMID 22936693.
Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, et al. (January 2019). "POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33". Scientific Reports. 9 (1): 102. Bibcode:2019NatSR...9..102H. doi:10.1038/s41598-018-36490-1. PMC 6331557. PMID 30643196.
Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, et al. (November 2003). "Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium". Hepatology. 38 (5): 1250–1257. doi:10.1053/jhep.2003.50446. PMID 14578864. S2CID 22691658.
Mohammed JP, Mattner J (July 2009). "Autoimmune disease triggered by infection with alphaproteobacteria". Expert Review of Clinical Immunology. 5 (4): 369–379. doi:10.1586/ECI.09.23. PMC 2742979. PMID 20161124.
Kaplan MM (November 2004). "Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis". The American Journal of Gastroenterology. 99 (11): 2147–2149. doi:10.1111/j.1572-0241.2004.41121.x. PMID 15554995. S2CID 19177405.
Selmi C, Gershwin ME (July 2004). "Bacteria and human autoimmunity: the case of primary biliary cirrhosis". Current Opinion in Rheumatology. 16 (4): 406–410. doi:10.1097/01.bor.0000130538.76808.c2. PMID 15201604. S2CID 23532625.
Mohammed JP, Fusakio ME, Rainbow DB, Moule C, Fraser HI, Clark J, et al. (July 2011). "Identification of Cd101 as a susceptibility gene for Novosphingobium aromaticivorans-induced liver autoimmunity". Journal of Immunology. 187 (1): 337–349. doi:10.4049/jimmunol.1003525. PMC 3134939. PMID 21613619.
Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, Mackay IR, et al. (March 2009). "Apotopes and the biliary specificity of primary biliary cirrhosis". Hepatology. 49 (3): 871–879. doi:10.1002/hep.22736. PMC 2665925. PMID 19185000.
Nakamura M, Takii Y, Ito M, Komori A, Yokoyama T, Shimizu-Yoshida Y, et al. (March 2006). "Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis". Journal of Autoimmunity. 26 (2): 138–145. doi:10.1016/j.jaut.2005.10.007. PMID 16337775.
Nickowitz RE, Worman HJ (December 1993). "Autoantibodies From Patients With Primary Biliary Cirrhosis Recognize a Restricted Region Within the Cytoplasmic Tail of Nuclear Pore Membrane Glycoprotein Gp210". The Journal of Experimental Medicine. 178 (6): 2237–2242. doi:10.1084/jem.178.6.2237. PMC 2191303. PMID 7504063.
Bauer A, Habior A (2007). "Measurement of gp210 autoantibodies in sera of patients with primary biliary cirrhosis". Journal of Clinical Laboratory Analysis. 21 (4): 227–231. doi:10.1002/jcla.20170. PMC 6648998. PMID 17621358.
Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. (January 2007). "Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis". Hepatology. 45 (1): 118–127. doi:10.1002/hep.21472. PMID 17187436. S2CID 19225707.
Nesher G, Margalit R, Ashkenazi YJ (April 2001). "Anti-nuclear envelope antibodies: Clinical associations". Seminars in Arthritis and Rheumatism. 30 (5): 313–320. doi:10.1053/sarh.2001.20266. PMID 11303304.
Nakanuma Y, Tsuneyama K, Sasaki M, Harada K (August 2000). "Destruction of bile ducts in primary biliary cirrhosis". Baillière's Best Practice & Research. Clinical Gastroenterology. 14 (4): 549–570. doi:10.1053/bega.2000.0103. PMID 10976014.
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M (January 2019). "Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases". Hepatology. 69 (1): 394–419. doi:10.1002/hep.30145. PMID 30070375.
Hirschfield, Gideon M.; Beuers, Ulrich; Corpechot, Christophe; Invernizzi, Pietro; Jones, David; Marzioni, Marco; Schramm, Christoph (July 2017). "EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis" (PDF). Journal of Hepatology. 67 (1): 145–172. doi:10.1016/j.jhep.2017.03.022. PMID 28427765.
Levy C, Lindor KD (April 2003). "Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis". Current Treatment Options in Gastroenterology. 6 (2): 93–103. doi:10.1007/s11938-003-0010-0. PMID 12628068. S2CID 37469838.
Oo YH, Neuberger J (2004). "Options for treatment of primary biliary cirrhosis". Drugs. 64 (20): 2261–2271. doi:10.2165/00003495-200464200-00001. PMID 15456326. S2CID 1288509.
Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C (December 2012). "Ursodeoxycholic acid for primary biliary cirrhosis". The Cochrane Database of Systematic Reviews. 12 (12): CD000551. doi:10.1002/14651858.CD000551.pub3. PMC 7045744. PMID 23235576.
Hirschfield, Gideon M.; Shiffman, Mitchell L.; Gulamhusein, Aliya; Kowdley, Kris V.; Vierling, John M.; Levy, Cynthia; Kremer, Andreas E.; Zigmond, Ehud; Andreone, Pietro; Gordon, Stuart C.; Bowlus, Christopher L.; Lawitz, Eric J.; Aspinall, Richard J.; Pratt, Daniel S.; Raikhelson, Karina; Gonzalez-Huezo, Maria S.; Heneghan, Michael A.; Jeong, Sook-Hyang; Ladrón de Guevara, Alma L.; Mayo, Marlyn J.; Dalekos, George N.; Drenth, Joost P.H.; Janczewska, Ewa; Leggett, Barbara A.; Nevens, Frederik; Vargas, Victor; Zuckerman, Eli; Corpechot, Christophe; Fassio, Eduardo; Hinrichsen, Holger; Invernizzi, Pietro; Trivedi, Palak J.; Forman, Lisa; Jones, David E.J.; Ryder, Stephen D.; Swain, Mark G.; Steinberg, Alexandra; Boudes, Pol F.; Choi, Yun-Jung; McWherter, Charles A. (6 April 2023). "Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study". Hepatology. 78 (2): 397–415. doi:10.1097/HEP.0000000000000395. hdl:11380/1319587.
Hasegawa, Sho; Yoneda, Masato; Kurita, Yusuke; Nogami, Asako; Honda, Yasushi; Hosono, Kunihiro; Nakajima, Atsushi (1 July 2021). "Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents". Drugs. 81 (10): 1181–1192. doi:10.1007/s40265-021-01545-7. ISSN 1179-1950. PMC 8282588.
Collier JD, Ninkovic M, Compston JE (February 2002). "Guidelines on the management of osteoporosis associated with chronic liver disease". Gut. 50 (Suppl 1): i1–i9. doi:10.1136/gut.50.suppl_1.i1. PMC 1867644. PMID 11788576.
Kaneko J, Sugawara Y, Tamura S, Aoki T, Hasegawa K, Yamashiki N, Kokudo N (January 2012). "Long-term outcome of living donor liver transplantation for primary biliary cirrhosis". Transplant International. 25 (1): 7–12. doi:10.1111/j.1432-2277.2011.01336.x. PMID 21923804. S2CID 19872625.
Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. (March 2013). "Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid". Gastroenterology. 144 (3): 560–569. doi:10.1053/j.gastro.2012.12.005. PMID 23246637.
Lleo A, Wang GQ, Gershwin ME, Hirschfield GM (December 2020). "Primary biliary cholangitis". Lancet. 396 (10266): 1915–1926. doi:10.1016/S0140-6736(20)31607-X. PMID 33308474. S2CID 228086916.
Cristoferi L, Nardi A, Ronca V, Invernizzi P, Mells G, Carbone M (December 2018). "Prognostic models in primary biliary cholangitis". Journal of Autoimmunity. 95 (1): 171–178. doi:10.1016/j.jaut.2018.10.024. PMID 30420264. S2CID 53292973.
Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, et al. (September 2018). "Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score". The Lancet. Gastroenterology & Hepatology. 3 (9): 626–634. doi:10.1016/S2468-1253(18)30163-8. PMC 6962055. PMID 30017646.
Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G, et al. (February 2004). "Frequency of monosomy X in women with primary biliary cirrhosis". Lancet. 363 (9408): 533–535. doi:10.1016/S0140-6736(04)15541-4. PMID 14975617. S2CID 5309.
Webb GJ, Ryan RP, Marshall TP, Hirschfield GM (December 2021). "The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude". Clinical Gastroenterology and Hepatology. 19 (12): 2587–2596. doi:10.1016/j.cgh.2021.01.029. PMC 8661127. PMID 33493696.
Reuben A (January 2003). "The serology of the Addison-Gull syndrome". Hepatology. 37 (1): 225–228. doi:10.1002/hep.510370134. PMID 12500211. S2CID 42297264.
Walker JG, Doniach D, Roitt IM, Sherlock S (April 1965). "Serological Tests in Diagnosis of Primary Biliary Cirrhosis". Lancet. 1 (7390): 827–831. doi:10.1016/s0140-6736(65)91372-3. PMID 14263538.
Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, James OF (1986). "Positive Antimitochondrial Antibody but Normal Alkaline Phosphatase: Is this Primary Biliary Cirrhosis?". Hepatology. 6 (6): 1279–1284. doi:10.1002/hep.1840060609. PMID 3793004. S2CID 13626588.
Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OF, Jones DE (November 2005). "Development, Validation, and Evaluation of the PBC-40, a Disease Specific Health-Related Quality of Life Measure for Primary Biliary Cirrhosis". Gut. 54 (11): 1622–1629. doi:10.1136/gut.2005.065862. PMC 1774759. PMID 15961522.
Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, et al. (March 2011). "Genome-Wide Association study Identifies 12 New Susceptibility Loci for Primary Biliary Cirrhosis". Nature Genetics. 43 (4): 329–332. doi:10.1038/ng.789. PMC 3071550. PMID 21399635.

handle.net

hdl.handle.net

Floreani A, Franceschet I, Cazzagon N (August 2014). "Primary biliary cirrhosis: overlaps with other autoimmune disorders". Seminars in Liver Disease. 34 (3): 352–360. doi:10.1055/s-0034-1383734. hdl:11577/3143751. PMID 25057958. S2CID 21382956.
Hirschfield, Gideon M.; Shiffman, Mitchell L.; Gulamhusein, Aliya; Kowdley, Kris V.; Vierling, John M.; Levy, Cynthia; Kremer, Andreas E.; Zigmond, Ehud; Andreone, Pietro; Gordon, Stuart C.; Bowlus, Christopher L.; Lawitz, Eric J.; Aspinall, Richard J.; Pratt, Daniel S.; Raikhelson, Karina; Gonzalez-Huezo, Maria S.; Heneghan, Michael A.; Jeong, Sook-Hyang; Ladrón de Guevara, Alma L.; Mayo, Marlyn J.; Dalekos, George N.; Drenth, Joost P.H.; Janczewska, Ewa; Leggett, Barbara A.; Nevens, Frederik; Vargas, Victor; Zuckerman, Eli; Corpechot, Christophe; Fassio, Eduardo; Hinrichsen, Holger; Invernizzi, Pietro; Trivedi, Palak J.; Forman, Lisa; Jones, David E.J.; Ryder, Stephen D.; Swain, Mark G.; Steinberg, Alexandra; Boudes, Pol F.; Choi, Yun-Jung; McWherter, Charles A. (6 April 2023). "Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study". Hepatology. 78 (2): 397–415. doi:10.1097/HEP.0000000000000395. hdl:11380/1319587.

harvard.edu

ui.adsabs.harvard.edu

Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, et al. (January 2019). "POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33". Scientific Reports. 9 (1): 102. Bibcode:2019NatSR...9..102H. doi:10.1038/s41598-018-36490-1. PMC 6331557. PMID 30643196.

ipsen.com

"Ipsen's Iqirvo receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis". Ipsen (Press release). 10 June 2024. Retrieved 11 June 2024.

nih.gov

pubmed.ncbi.nlm.nih.gov

Poupon R (May 2010). "Primary biliary cirrhosis: a 2010 update". Journal of Hepatology. 52 (5): 745–758. doi:10.1016/j.jhep.2009.11.027. PMID 20347176.
Hirschfield GM, Gershwin ME (January 2013). "The immunobiology and pathophysiology of primary biliary cirrhosis". Annual Review of Pathology. 8: 303–330. doi:10.1146/annurev-pathol-020712-164014. PMID 23347352.
Selmi C, Bowlus CL, Gershwin ME, Coppel RL (May 2011). "Primary biliary cirrhosis". Lancet. 377 (9777): 1600–1609. doi:10.1016/S0140-6736(10)61965-4. PMID 21529926. S2CID 2741153.
Boonstra K, Beuers U, Ponsioen CY (May 2012). "Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review". Journal of Hepatology. 56 (5): 1181–1188. doi:10.1016/j.jhep.2011.10.025. PMID 22245904.
James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV (August 1999). "Primary biliary cirrhosis once rare, now common in the United Kingdom?". Hepatology. 30 (2): 390–394. doi:10.1002/hep.510300213. PMID 10421645. S2CID 25248575.
Moulton, Vaishali R. (2018). "Sex Hormones in Acquired Immunity and Autoimmune Disease". Frontiers in Immunology. 9: 2279. doi:10.3389/fimmu.2018.02279. ISSN 1664-3224. PMC 6180207. PMID 30337927.
Dauphinee JA, Sinclair JC (July 1949). "Primary biliary cirrhosis". Canadian Medical Association Journal. 61 (1): 1–6. PMC 1591584. PMID 18153470.
Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ (July 2009). "Primary biliary cirrhosis". Hepatology. 50 (1): 291–308. doi:10.1002/hep.22906. PMID 19554543. S2CID 439839. The AASLD Practice Guideline
Floreani A, Franceschet I, Cazzagon N (August 2014). "Primary biliary cirrhosis: overlaps with other autoimmune disorders". Seminars in Liver Disease. 34 (3): 352–360. doi:10.1055/s-0034-1383734. hdl:11577/3143751. PMID 25057958. S2CID 21382956.
Vierling JM (February 2004). "Primary Biliary Cirrhosis and Autoimmune Cholangiopathy". Clinics in Liver Disease. 8 (1): 177–194. doi:10.1016/S1089-3261(03)00132-6. PMID 15062200.
Narciso-Schiavon JL, Schiavon LL (February 2017). "To screen or not to screen? Celiac antibodies in liver diseases". World Journal of Gastroenterology (Review). 23 (5): 776–791. doi:10.3748/wjg.v23.i5.776. PMC 5296194. PMID 28223722.
Volta U, Rodrigo L, Granito A, Petrolini N, Muratori P, Muratori L, et al. (October 2002). "Celiac disease in autoimmune cholestatic liver disorders". The American Journal of Gastroenterology. 97 (10): 2609–2613. doi:10.1111/j.1572-0241.2002.06031.x. PMID 12385447. S2CID 17375127.
Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. (June 2009). "Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants". The New England Journal of Medicine. 360 (24): 2544–2555. doi:10.1056/NEJMoa0810440. PMC 2857316. PMID 19458352.
Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, et al. (October 2012). "Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis". Nature Genetics. 44 (10): 1137–1141. doi:10.1038/ng.2395. PMC 3459817. PMID 22961000.
Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, et al. (December 2012). "Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants". Human Molecular Genetics. 21 (23): 5209–5221. doi:10.1093/hmg/dds359. PMC 3490520. PMID 22936693.
Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, et al. (January 2019). "POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33". Scientific Reports. 9 (1): 102. Bibcode:2019NatSR...9..102H. doi:10.1038/s41598-018-36490-1. PMC 6331557. PMID 30643196.
Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, et al. (November 2003). "Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium". Hepatology. 38 (5): 1250–1257. doi:10.1053/jhep.2003.50446. PMID 14578864. S2CID 22691658.
Mohammed JP, Mattner J (July 2009). "Autoimmune disease triggered by infection with alphaproteobacteria". Expert Review of Clinical Immunology. 5 (4): 369–379. doi:10.1586/ECI.09.23. PMC 2742979. PMID 20161124.
Kaplan MM (November 2004). "Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis". The American Journal of Gastroenterology. 99 (11): 2147–2149. doi:10.1111/j.1572-0241.2004.41121.x. PMID 15554995. S2CID 19177405.
Selmi C, Gershwin ME (July 2004). "Bacteria and human autoimmunity: the case of primary biliary cirrhosis". Current Opinion in Rheumatology. 16 (4): 406–410. doi:10.1097/01.bor.0000130538.76808.c2. PMID 15201604. S2CID 23532625.
Mohammed JP, Fusakio ME, Rainbow DB, Moule C, Fraser HI, Clark J, et al. (July 2011). "Identification of Cd101 as a susceptibility gene for Novosphingobium aromaticivorans-induced liver autoimmunity". Journal of Immunology. 187 (1): 337–349. doi:10.4049/jimmunol.1003525. PMC 3134939. PMID 21613619.
Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, Mackay IR, et al. (March 2009). "Apotopes and the biliary specificity of primary biliary cirrhosis". Hepatology. 49 (3): 871–879. doi:10.1002/hep.22736. PMC 2665925. PMID 19185000.
Nakamura M, Takii Y, Ito M, Komori A, Yokoyama T, Shimizu-Yoshida Y, et al. (March 2006). "Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis". Journal of Autoimmunity. 26 (2): 138–145. doi:10.1016/j.jaut.2005.10.007. PMID 16337775.
Nickowitz RE, Worman HJ (December 1993). "Autoantibodies From Patients With Primary Biliary Cirrhosis Recognize a Restricted Region Within the Cytoplasmic Tail of Nuclear Pore Membrane Glycoprotein Gp210". The Journal of Experimental Medicine. 178 (6): 2237–2242. doi:10.1084/jem.178.6.2237. PMC 2191303. PMID 7504063.
Bauer A, Habior A (2007). "Measurement of gp210 autoantibodies in sera of patients with primary biliary cirrhosis". Journal of Clinical Laboratory Analysis. 21 (4): 227–231. doi:10.1002/jcla.20170. PMC 6648998. PMID 17621358.
Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. (January 2007). "Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis". Hepatology. 45 (1): 118–127. doi:10.1002/hep.21472. PMID 17187436. S2CID 19225707.
Nesher G, Margalit R, Ashkenazi YJ (April 2001). "Anti-nuclear envelope antibodies: Clinical associations". Seminars in Arthritis and Rheumatism. 30 (5): 313–320. doi:10.1053/sarh.2001.20266. PMID 11303304.
Nakanuma Y, Tsuneyama K, Sasaki M, Harada K (August 2000). "Destruction of bile ducts in primary biliary cirrhosis". Baillière's Best Practice & Research. Clinical Gastroenterology. 14 (4): 549–570. doi:10.1053/bega.2000.0103. PMID 10976014.
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M (January 2019). "Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases". Hepatology. 69 (1): 394–419. doi:10.1002/hep.30145. PMID 30070375.
Hirschfield, Gideon M.; Beuers, Ulrich; Corpechot, Christophe; Invernizzi, Pietro; Jones, David; Marzioni, Marco; Schramm, Christoph (July 2017). "EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis" (PDF). Journal of Hepatology. 67 (1): 145–172. doi:10.1016/j.jhep.2017.03.022. PMID 28427765.
Levy C, Lindor KD (April 2003). "Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis". Current Treatment Options in Gastroenterology. 6 (2): 93–103. doi:10.1007/s11938-003-0010-0. PMID 12628068. S2CID 37469838.
Oo YH, Neuberger J (2004). "Options for treatment of primary biliary cirrhosis". Drugs. 64 (20): 2261–2271. doi:10.2165/00003495-200464200-00001. PMID 15456326. S2CID 1288509.
Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C (December 2012). "Ursodeoxycholic acid for primary biliary cirrhosis". The Cochrane Database of Systematic Reviews. 12 (12): CD000551. doi:10.1002/14651858.CD000551.pub3. PMC 7045744. PMID 23235576.
Collier JD, Ninkovic M, Compston JE (February 2002). "Guidelines on the management of osteoporosis associated with chronic liver disease". Gut. 50 (Suppl 1): i1–i9. doi:10.1136/gut.50.suppl_1.i1. PMC 1867644. PMID 11788576.
Kaneko J, Sugawara Y, Tamura S, Aoki T, Hasegawa K, Yamashiki N, Kokudo N (January 2012). "Long-term outcome of living donor liver transplantation for primary biliary cirrhosis". Transplant International. 25 (1): 7–12. doi:10.1111/j.1432-2277.2011.01336.x. PMID 21923804. S2CID 19872625.
Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. (March 2013). "Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid". Gastroenterology. 144 (3): 560–569. doi:10.1053/j.gastro.2012.12.005. PMID 23246637.
Lleo A, Wang GQ, Gershwin ME, Hirschfield GM (December 2020). "Primary biliary cholangitis". Lancet. 396 (10266): 1915–1926. doi:10.1016/S0140-6736(20)31607-X. PMID 33308474. S2CID 228086916.
Cristoferi L, Nardi A, Ronca V, Invernizzi P, Mells G, Carbone M (December 2018). "Prognostic models in primary biliary cholangitis". Journal of Autoimmunity. 95 (1): 171–178. doi:10.1016/j.jaut.2018.10.024. PMID 30420264. S2CID 53292973.
Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, et al. (September 2018). "Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score". The Lancet. Gastroenterology & Hepatology. 3 (9): 626–634. doi:10.1016/S2468-1253(18)30163-8. PMC 6962055. PMID 30017646.
Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G, et al. (February 2004). "Frequency of monosomy X in women with primary biliary cirrhosis". Lancet. 363 (9408): 533–535. doi:10.1016/S0140-6736(04)15541-4. PMID 14975617. S2CID 5309.
Webb GJ, Ryan RP, Marshall TP, Hirschfield GM (December 2021). "The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude". Clinical Gastroenterology and Hepatology. 19 (12): 2587–2596. doi:10.1016/j.cgh.2021.01.029. PMC 8661127. PMID 33493696.
Reuben A (January 2003). "The serology of the Addison-Gull syndrome". Hepatology. 37 (1): 225–228. doi:10.1002/hep.510370134. PMID 12500211. S2CID 42297264.
Walker JG, Doniach D, Roitt IM, Sherlock S (April 1965). "Serological Tests in Diagnosis of Primary Biliary Cirrhosis". Lancet. 1 (7390): 827–831. doi:10.1016/s0140-6736(65)91372-3. PMID 14263538.
Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, James OF (1986). "Positive Antimitochondrial Antibody but Normal Alkaline Phosphatase: Is this Primary Biliary Cirrhosis?". Hepatology. 6 (6): 1279–1284. doi:10.1002/hep.1840060609. PMID 3793004. S2CID 13626588.
Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OF, Jones DE (November 2005). "Development, Validation, and Evaluation of the PBC-40, a Disease Specific Health-Related Quality of Life Measure for Primary Biliary Cirrhosis". Gut. 54 (11): 1622–1629. doi:10.1136/gut.2005.065862. PMC 1774759. PMID 15961522.
Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, et al. (March 2011). "Genome-Wide Association study Identifies 12 New Susceptibility Loci for Primary Biliary Cirrhosis". Nature Genetics. 43 (4): 329–332. doi:10.1038/ng.789. PMC 3071550. PMID 21399635.

ncbi.nlm.nih.gov

Moulton, Vaishali R. (2018). "Sex Hormones in Acquired Immunity and Autoimmune Disease". Frontiers in Immunology. 9: 2279. doi:10.3389/fimmu.2018.02279. ISSN 1664-3224. PMC 6180207. PMID 30337927.
Dauphinee JA, Sinclair JC (July 1949). "Primary biliary cirrhosis". Canadian Medical Association Journal. 61 (1): 1–6. PMC 1591584. PMID 18153470.
Narciso-Schiavon JL, Schiavon LL (February 2017). "To screen or not to screen? Celiac antibodies in liver diseases". World Journal of Gastroenterology (Review). 23 (5): 776–791. doi:10.3748/wjg.v23.i5.776. PMC 5296194. PMID 28223722.
Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. (June 2009). "Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants". The New England Journal of Medicine. 360 (24): 2544–2555. doi:10.1056/NEJMoa0810440. PMC 2857316. PMID 19458352.
Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, et al. (October 2012). "Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis". Nature Genetics. 44 (10): 1137–1141. doi:10.1038/ng.2395. PMC 3459817. PMID 22961000.
Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, et al. (December 2012). "Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants". Human Molecular Genetics. 21 (23): 5209–5221. doi:10.1093/hmg/dds359. PMC 3490520. PMID 22936693.
Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, et al. (January 2019). "POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33". Scientific Reports. 9 (1): 102. Bibcode:2019NatSR...9..102H. doi:10.1038/s41598-018-36490-1. PMC 6331557. PMID 30643196.
Mohammed JP, Mattner J (July 2009). "Autoimmune disease triggered by infection with alphaproteobacteria". Expert Review of Clinical Immunology. 5 (4): 369–379. doi:10.1586/ECI.09.23. PMC 2742979. PMID 20161124.
Mohammed JP, Fusakio ME, Rainbow DB, Moule C, Fraser HI, Clark J, et al. (July 2011). "Identification of Cd101 as a susceptibility gene for Novosphingobium aromaticivorans-induced liver autoimmunity". Journal of Immunology. 187 (1): 337–349. doi:10.4049/jimmunol.1003525. PMC 3134939. PMID 21613619.
Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, Mackay IR, et al. (March 2009). "Apotopes and the biliary specificity of primary biliary cirrhosis". Hepatology. 49 (3): 871–879. doi:10.1002/hep.22736. PMC 2665925. PMID 19185000.
Nickowitz RE, Worman HJ (December 1993). "Autoantibodies From Patients With Primary Biliary Cirrhosis Recognize a Restricted Region Within the Cytoplasmic Tail of Nuclear Pore Membrane Glycoprotein Gp210". The Journal of Experimental Medicine. 178 (6): 2237–2242. doi:10.1084/jem.178.6.2237. PMC 2191303. PMID 7504063.
Bauer A, Habior A (2007). "Measurement of gp210 autoantibodies in sera of patients with primary biliary cirrhosis". Journal of Clinical Laboratory Analysis. 21 (4): 227–231. doi:10.1002/jcla.20170. PMC 6648998. PMID 17621358.
Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C (December 2012). "Ursodeoxycholic acid for primary biliary cirrhosis". The Cochrane Database of Systematic Reviews. 12 (12): CD000551. doi:10.1002/14651858.CD000551.pub3. PMC 7045744. PMID 23235576.
Hasegawa, Sho; Yoneda, Masato; Kurita, Yusuke; Nogami, Asako; Honda, Yasushi; Hosono, Kunihiro; Nakajima, Atsushi (1 July 2021). "Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents". Drugs. 81 (10): 1181–1192. doi:10.1007/s40265-021-01545-7. ISSN 1179-1950. PMC 8282588.
Collier JD, Ninkovic M, Compston JE (February 2002). "Guidelines on the management of osteoporosis associated with chronic liver disease". Gut. 50 (Suppl 1): i1–i9. doi:10.1136/gut.50.suppl_1.i1. PMC 1867644. PMID 11788576.
Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, et al. (September 2018). "Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score". The Lancet. Gastroenterology & Hepatology. 3 (9): 626–634. doi:10.1016/S2468-1253(18)30163-8. PMC 6962055. PMID 30017646.
Webb GJ, Ryan RP, Marshall TP, Hirschfield GM (December 2021). "The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude". Clinical Gastroenterology and Hepatology. 19 (12): 2587–2596. doi:10.1016/j.cgh.2021.01.029. PMC 8661127. PMID 33493696.
Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OF, Jones DE (November 2005). "Development, Validation, and Evaluation of the PBC-40, a Disease Specific Health-Related Quality of Life Measure for Primary Biliary Cirrhosis". Gut. 54 (11): 1622–1629. doi:10.1136/gut.2005.065862. PMC 1774759. PMID 15961522.
Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, et al. (March 2011). "Genome-Wide Association study Identifies 12 New Susceptibility Loci for Primary Biliary Cirrhosis". Nature Genetics. 43 (4): 329–332. doi:10.1038/ng.789. PMC 3071550. PMID 21399635.

pbcers.org

"Primary Biliary Cirrhosis Name Change Initiative" (PDF). PBCers Organization. Archived from the original (PDF) on April 19, 2015. Retrieved September 15, 2022.

pbcfoundation.org.uk

PBC Foundation (UK). "PBC Name Change". Retrieved 27 Jan 2017.
PBC Foundation. "EASL Name Change Presentation". Archived from the original on 9 July 2015. Retrieved 8 July 2015.

scotsman.com

Staff (3 January 2008). "Dealing with a silent killer". The Scotsman.
Gordon B (31 December 2003). "A royal seal of approval". The Scotsman.

semanticscholar.org

api.semanticscholar.org

Selmi C, Bowlus CL, Gershwin ME, Coppel RL (May 2011). "Primary biliary cirrhosis". Lancet. 377 (9777): 1600–1609. doi:10.1016/S0140-6736(10)61965-4. PMID 21529926. S2CID 2741153.
James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV (August 1999). "Primary biliary cirrhosis once rare, now common in the United Kingdom?". Hepatology. 30 (2): 390–394. doi:10.1002/hep.510300213. PMID 10421645. S2CID 25248575.
Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ (July 2009). "Primary biliary cirrhosis". Hepatology. 50 (1): 291–308. doi:10.1002/hep.22906. PMID 19554543. S2CID 439839. The AASLD Practice Guideline
Floreani A, Franceschet I, Cazzagon N (August 2014). "Primary biliary cirrhosis: overlaps with other autoimmune disorders". Seminars in Liver Disease. 34 (3): 352–360. doi:10.1055/s-0034-1383734. hdl:11577/3143751. PMID 25057958. S2CID 21382956.
Volta U, Rodrigo L, Granito A, Petrolini N, Muratori P, Muratori L, et al. (October 2002). "Celiac disease in autoimmune cholestatic liver disorders". The American Journal of Gastroenterology. 97 (10): 2609–2613. doi:10.1111/j.1572-0241.2002.06031.x. PMID 12385447. S2CID 17375127.
Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, et al. (November 2003). "Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium". Hepatology. 38 (5): 1250–1257. doi:10.1053/jhep.2003.50446. PMID 14578864. S2CID 22691658.
Kaplan MM (November 2004). "Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis". The American Journal of Gastroenterology. 99 (11): 2147–2149. doi:10.1111/j.1572-0241.2004.41121.x. PMID 15554995. S2CID 19177405.
Selmi C, Gershwin ME (July 2004). "Bacteria and human autoimmunity: the case of primary biliary cirrhosis". Current Opinion in Rheumatology. 16 (4): 406–410. doi:10.1097/01.bor.0000130538.76808.c2. PMID 15201604. S2CID 23532625.
Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. (January 2007). "Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis". Hepatology. 45 (1): 118–127. doi:10.1002/hep.21472. PMID 17187436. S2CID 19225707.
Levy C, Lindor KD (April 2003). "Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis". Current Treatment Options in Gastroenterology. 6 (2): 93–103. doi:10.1007/s11938-003-0010-0. PMID 12628068. S2CID 37469838.
Oo YH, Neuberger J (2004). "Options for treatment of primary biliary cirrhosis". Drugs. 64 (20): 2261–2271. doi:10.2165/00003495-200464200-00001. PMID 15456326. S2CID 1288509.
Kaneko J, Sugawara Y, Tamura S, Aoki T, Hasegawa K, Yamashiki N, Kokudo N (January 2012). "Long-term outcome of living donor liver transplantation for primary biliary cirrhosis". Transplant International. 25 (1): 7–12. doi:10.1111/j.1432-2277.2011.01336.x. PMID 21923804. S2CID 19872625.
Lleo A, Wang GQ, Gershwin ME, Hirschfield GM (December 2020). "Primary biliary cholangitis". Lancet. 396 (10266): 1915–1926. doi:10.1016/S0140-6736(20)31607-X. PMID 33308474. S2CID 228086916.
Cristoferi L, Nardi A, Ronca V, Invernizzi P, Mells G, Carbone M (December 2018). "Prognostic models in primary biliary cholangitis". Journal of Autoimmunity. 95 (1): 171–178. doi:10.1016/j.jaut.2018.10.024. PMID 30420264. S2CID 53292973.
Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G, et al. (February 2004). "Frequency of monosomy X in women with primary biliary cirrhosis". Lancet. 363 (9408): 533–535. doi:10.1016/S0140-6736(04)15541-4. PMID 14975617. S2CID 5309.
Reuben A (January 2003). "The serology of the Addison-Gull syndrome". Hepatology. 37 (1): 225–228. doi:10.1002/hep.510370134. PMID 12500211. S2CID 42297264.
Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, James OF (1986). "Positive Antimitochondrial Antibody but Normal Alkaline Phosphatase: Is this Primary Biliary Cirrhosis?". Hepatology. 6 (6): 1279–1284. doi:10.1002/hep.1840060609. PMID 3793004. S2CID 13626588.

uk-pbc.com

"UK-PBC – Stratified Medicine in Primary Biliary Cholangitis (PBC; formally known as Cirrhosis)".

web.archive.org

"Primary Biliary Cirrhosis Name Change Initiative" (PDF). PBCers Organization. Archived from the original (PDF) on April 19, 2015. Retrieved September 15, 2022.
Association of Medical Research Charities. "The PBC Foundation". Archived from the original on 4 March 2016. Retrieved 12 July 2015.
Thain C (2015). "Primary Biliary Cirrhosis: Getting a Diagnosis". At Home Magazine. Archived from the original (online) on 13 July 2015. Retrieved 28 July 2015.
PBC Foundation. "EASL Name Change Presentation". Archived from the original on 9 July 2015. Retrieved 8 July 2015.

worldcat.org

Moulton, Vaishali R. (2018). "Sex Hormones in Acquired Immunity and Autoimmune Disease". Frontiers in Immunology. 9: 2279. doi:10.3389/fimmu.2018.02279. ISSN 1664-3224. PMC 6180207. PMID 30337927.
Hasegawa, Sho; Yoneda, Masato; Kurita, Yusuke; Nogami, Asako; Honda, Yasushi; Hosono, Kunihiro; Nakajima, Atsushi (1 July 2021). "Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents". Drugs. 81 (10): 1181–1192. doi:10.1007/s40265-021-01545-7. ISSN 1179-1950. PMC 8282588.